TP53 and hepatocellular carcinoma: Several studies have reported a potential interaction between the MDM2 SNP309 and the p53 Arg72Pro polymorphisms for breast and endometrial cancer, gastric cardia adenocarcinoma, and hepatitis B virus-related hepatocellular carcinoma [34]–[37].